Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

RENAL CELL CARCINOMA

New insights into the obesity paradox in renal cell carcinoma

Nature Reviews Nephrology volume 16, pages 253–254 (2020)Cite this article

Subjects

Paradoxically, elevated BMI is a recognized positive prognostic factor in renal cell carcinoma (RCC). A recent investigation of the transcriptomic signatures of RCC tumours and peritumoural tissues suggests potential biological mechanisms underlying this effect. However, the clinical utility of BMI in the context of RCC remains uncertain.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: RCC tumour and microenvironment in patients with normal weight versus obesity.

References

  1. Calle, E. E. & Kaaks, R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 4, 579–591 (2004).

    Article  CAS  Google Scholar 

  2. Choueiri, T. K. et al. The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: results from a large international collaboration. J. Clin. Oncol. 28 (Suppl. 15), 4524 (2010).

    Article  Google Scholar 

  3. Cespedes Feliciano, E. M., Kroenke, C. H. & Caan, B. J. The obesity paradox in cancer: how important is muscle? Annu. Rev. Nutr. 38, 357–379 (2018).

    Article  CAS  Google Scholar 

  4. Clark, A. L., Fonarow, G. C. & Horwich, T. B. Obesity and the obesity paradox in heart Ffailure. Prog. Cardiovasc. Dis. 56, 409–414 (2014).

    Article  Google Scholar 

  5. Baracos, V. E. & Arribas, L. Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy. Ann. Oncol. 29 (Suppl. 2), ii1–ii9 (2018).

    Article  CAS  Google Scholar 

  6. Sanchez, A. et al. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. Lancet Oncol. 21, 283–293 (2020).

    Article  Google Scholar 

  7. Albiges, L. et al. Body mass index and metastatic renal cell carcinoma: clinical and biological correlations. J. Clin. Oncol. 34, 3655–3663 (2016).

    Article  CAS  Google Scholar 

  8. McQuade, J. L. et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 19, 310–322 (2018).

    Article  Google Scholar 

  9. McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749–757 (2018).

    Article  CAS  Google Scholar 

  10. Heng, D. Y. et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 14, 141–148 (2013).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada

    Chun Loo Gan & Daniel Y. C. Heng

Authors
  1. Chun Loo Gan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Y. C. Heng
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel Y. C. Heng.

Ethics declarations

Competing interests

D.Y.C.H. acts in an advisory role at Pfizer, Novartis, Bristol-Myers Squibb, Janssen, Astellas Pharma, Ipsen, Eisai and Merck. C.L.G. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gan, C.L., Heng, D.Y.C. New insights into the obesity paradox in renal cell carcinoma. Nat Rev Nephrol 16, 253–254 (2020). https://doi.org/10.1038/s41581-020-0264-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-020-0264-y

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer